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cross-sectional, retrospective study without randomization cannot
lead us to any causal conclusions about statins and intraplaque
angiogenesis. However, there are strong indications favoring that
hypothesis. Vascular endothelial growth factor is a well-recognized
and potent angiogenetic factor. It is known that pravastatin, but
also fenofibrate, reduces vascular endothelial growth factor plasma
levels in humans (3).
These findings raise the question of whether statins are the
antiangiogenetic factor for which we are searching. To answer this
question, further investigation is needed, and maybe it is time for
a randomized trial with standard dose and duration of treatment to
test the effect on intraplaque angiogenesis.
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Reply
Koutouzis et al. (1) propose the paradigm of statins eliminating
plaque angiogenesis and, thus, lesion instability. These authors
recently showed pathologic data of reduced microvascular density
in carotid plaques from patients receiving statins at least 3 months.
However, direct evidence of decreased intraplaque angiogenesis
attributed to statins and clinical improvement is lacking. More-
over, magnetic resonance imaging shows statins to be more
effective in debulking nonhemorrhagic plaques as necrotic core
volume in lesions with intraplaque hemorrhage increases, despite
statin use (2). Large-scale clinical trials in parallel angiogenic disor-
ders such as age-related macular degeneration (3) or tumor growth (4)
have failed to show a consistent association between statins and
disease regression. These results are in opposition to the potent
antiangiogenic effects of statins in angiogenic assays (5) or animal
models (6).
Although statins down-regulate various gene products that
mediate cell proliferation, including vascular endothelial growth
factor (7), there is an increasing redundancy of angiogenic factors
creating the potential to circumvent drugs targeting specific path-
ways (8). Further, the expression of pro- and antiangiogenic
mediators is likely dependent on lesion stage, possibly compromis-
ing the efficacy of a single drug. The identification of reliable
biomarkers or imaging methods to gauge the effectiveness of
antiangiogenic therapy also remains an obstacle because the cur-
rent end point is limited to evaluation of surgical tissue.
Finally, it is not clear whether decreased neovascularlization or
“normalization” of existing vessels is the more favorable approach
because the pathology is not dictated by the mere presence of
vessels, but by the fact that these structures are dysfunctional as
they are fragile and leaky. A normalized, less leaky vasculature,
characterized by a more restrictive basement membrane sur-
rounded by pericytes (9), may support a more favorable microen-
vironment promoting plaque stabilization.
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